A Phase 1, Single-center, Open-label, Dose-Rising Clinical Trial to Evaluate the Pharmacokinetics, Safety and Tolerability of Treprostinil Inhalation Powder (TrIP) in Healthy Normal Volunteers
Phase of Trial: Phase I
Latest Information Update: 23 Mar 2018
At a glance
- Drugs Treprostinil (Primary)
- Indications Pulmonary arterial hypertension
- Focus Adverse reactions
- Sponsors MannKind Corporation
- 16 Mar 2018 Status changed from not yet recruiting to recruiting.
- 07 Mar 2018 Status changed from planning to not yet recruiting.
- 07 Mar 2018 New trial record